HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.
Genticel (France) a clinical-stage biopharmaceutical company focused on therapeutic vaccines for the prevention of cervical cancer in HPV infected women, closed a $17.7M Series C financing. Participants include AGF Private Equity, Institut Régional de Développement Industriel, Amundi Private Equity Funds, InnoBio Fund and Edmond de Rothschild Investment Partners.
VaxInnate (Cranbury, NJ) a clinical-stage vaccine company focused on infectious disease including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus, closed a $30M Series D financing. Participants include Wellcome Trust, New Leaf Venture Partners, Canaan Partners, HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures and CHL Medical Partners.